History

1983
1983

Founded In 1983

Founded In 1983
Virchow Labs established for manufacture of Sulfamethoxazole API.
2001
2001

In 2001

Virchow Biotech incorporated for manufacture of recombinant and classical biologicals in collaboration with US based scientist group.
2001

In 2001

In 2001
Saraca Labs becomes part of Virchow Group through majority share acquisition by promoters of Virchow Group.
2002
2002

In 2002

In 2002
Covalent Labs incorporated for manufacture of oral Cephalosporin APIs.
2003
2003

In 2003

First US FDA approval in Group for Virchow Labs.
2004
2004

In 2004

Acquisition of Andhra Organics in Vizag. 100 acre site with adequate facilities for future expansions.
2007
2007

In 2007

Started manufacture of GCLE, a key Cephalosporin intermediate at Virchow Petrochemicals.
2009
2009

In 2009

Started marketing of formulations in international markets
2011
2011

In 2011

Group revenues cross Rs 1,000 crore.
2012
2012

In 2012

Foray into branded formulation marketing in India.
2012

In 2012

Started manufacture of Sterile Cephalosporins at Covalent.
2014
2014

IN 2014

Group revenues cross Rs 2,000 crore.
2017
2017

In 2017

Group revenues cross 3000 Cores ($500 Million).